Novel potassium ion response type drug-loaded liposome and preparation method thereof

The potassium ion-responsive liposome addresses low enrichment and retention issues by self-assembling at tumor sites, enhancing drug efficacy through targeted delivery and increased uptake.

CN119074941APending Publication Date: 2024-12-06CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411180608.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing liposome drug delivery systems face challenges such as low enrichment, short retention time, and poor specificity at tumor sites due to insufficient drug utilization, despite advances in stimulus-responsive materials that target tumor microenvironments.

Method used

A novel potassium ion-responsive drug-loaded liposome composed of a potassium ion recognition copolymer, which self-assembles at abnormal potassium ion concentrations in tumor microenvironments, enhancing tumor cell uptake and retention time.

Benefits of technology

The liposome system improves drug efficacy by prolonging retention time and increasing tumor cell uptake rates, offering a targeted intelligent nano drug delivery system with good biocompatibility and versatility for various drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074941A_ABST
    Figure CN119074941A_ABST
Patent Text Reader

Abstract

The invention discloses a potassium ion response type drug-loaded liposome and a preparation method thereof, the potassium ion response type drug-loaded liposome is formed by modifying a drug-loaded liposome through a novel potassium ion recognition type copolymer, and a drug is embedded in a liposome core; the self-assembled novel liposome can specifically respond to potassium ions with abnormal concentration (40-50mM) in a tumor microenvironment to generate self-assembled novel liposome, the residence time of tumor tissue parts is prolonged, the tumor cell uptake rate is enhanced, the drug curative effect is improved, and the self-assembled novel liposome has important significance on tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel potassium ion responsive drug-loaded liposome and a preparation method thereof, in particular to a novel liposome which can specifically respond to abnormal concentration (40-50 mM) of potassium ions in a tumor microenvironment and undergo self-assembly. Background Art

[0002] Nano drug delivery systems can improve the biodistribution and pharmacokinetic behavior of drugs in the body, enhance drug efficacy and reduce drug toxicity and side effects. They have been widely studied in recent decades. There are many types of nano drug delivery systems, and liposomes have always been a hot research and development topic in this field. The first doxorubicin liposome It was successfully launched in 1995, and along with the cytarabine / daunorubicin compound liposome The first siRNA liposome In the past two years, liposomes have been approved for marketing by the FDA, injecting new vitality into the research and development of liposomes. Liposomes have a special phospholipid bilayer vesicle structure, which can be loaded with hydrophilic drugs, hydrophobic drugs and nucleic acids, etc., and have good biocompatibility. It is an ideal nano drug delivery system. Studies have shown that most liposome drugs can effectively reduce drug toxicity and side effects, but there are problems such as low enrichment in tumor sites, short retention time, and poor specificity, which in turn affect the efficacy.

[0003] To address this problem, stimulus-responsive materials are used to construct stimulus-responsive targeted liposomes. Although the smart liposomes constructed with stimulus-responsive materials cannot directly target tumor cell structures, they can respond to stimulation signals such as abnormal pH and enzymes in the tumor microenvironment to undergo changes in physical and chemical properties, achieve passive targeted enrichment of drugs at the tumor site, and have good stability, which has attracted more and more attention. However, common stimulus-responsive liposomes such as pH and enzymes still have problems such as insufficient drug utilization.

[0004] Potassium ion (K + ) is the main cation in the intracellular fluid of organisms. 98% of potassium salts in the human body are present in the intracellular fluid, and 2% of potassium salts are present in the extracellular fluid. In normal organisms, K + The concentration is about 3.5-5.5 mM, and K in intracellular fluid + The concentration is about 150mM, which is about 30 times that of the extracellular fluid. Recent research results show that some tumor sites involve a large number of cell apoptosis and necrosis, which causes K in the interstitial space of tumor cells. + The concentration abnormally rises to about 40-50 mM, which is about 10 times that of normal tissue fluid.

[0005] Here, the patent application with application number 201510299844.5 proposed “K +Responsive targeted intracellular drug release amphiphilic block copolymer drug-loaded micelles and preparation method thereof", benzo-15-crown-5-acrylamide was introduced into block polymer, and a K+ responsive targeted intracellular drug release amphiphilic block copolymer drug-loaded micelle was designed and prepared; and the patent application number 201610945016.9 proposed "a K+ responsive targeted intracellular drug release amphiphilic block copolymer drug-loaded micelle + Responsive amphiphilic block copolymer drug-loaded micelles and preparation methods thereof”, after the drug-loaded micelles release the drug in vivo, the block copolymers can be excreted from the body through normal metabolic pathways to avoid accumulation in the body and causing potential toxicity. The potassium ion-responsive nano drug delivery systems in the above two schemes are micelles, and no disclosure is made on potassium ion-responsive liposomes.

[0006] Therefore, the present invention aims at the characteristics of abnormal K+ concentration in the tumor microenvironment and constructs a specific response to K+. + The smart liposomes provide a new idea and method for the treatment of tumors. Summary of the invention

[0007] In view of the deficiencies in the above-mentioned prior art, the present invention proposes a novel liposome that can specifically respond to abnormal concentrations (40-50 mM) of potassium ions in the tumor microenvironment and undergo self-assembly, and a preparation method thereof, thereby prolonging the retention time in the tumor tissue site and enhancing the tumor cell uptake rate, thereby improving the efficacy of the drug, which is of great significance for the treatment of tumors.

[0008] In order to achieve the above object, the technical scheme of the present invention is: a novel potassium ion responsive drug-loaded liposome, which is composed of a potassium ion recognition copolymer modified drug-loaded liposome, and the drug is embedded in the inner core of the liposome, wherein the content of the drug in the drug-loaded liposome is 3-10wt%; the particle size of the drug-loaded liposome is 70-200nm, and the potassium ion recognition copolymer is poly (N-isopropyl acrylamide-co-benzo 15 crown 5 acrylamide-co-N, N-dimethyl acrylamide)-co-distearoyl phosphatidylethanolamine, and its structural formula is as follows:

[0009]

[0010] Among them, y / (x+y+z)=0.1~0.4, z / (x+y+z)=0.2~0.5, x+y+z=10~300.

[0011] Furthermore, the preparation method of the potassium ion recognition copolymer is as follows:

[0012] S1. Take N-isopropylacrylamide, benzo-15-crown-5 acrylamide, azobisisobutyronitrile, N,N-dimethylacrylamide, and 2-(dodecyl trithiocarbonate)-2-methylpropionic acid, and add 1,4-dioxane to dissolve;

[0013] S2, introducing nitrogen into the solution in step S1 to remove oxygen in the solution, and sealing and reacting at a temperature of 60°C to 80°C for 6 to 24 hours;

[0014] S3. After the reaction is completed, the reaction solution is diluted with tetrahydrofuran, the diluted reaction solution is added to anhydrous ether or methyl tert-butyl ether for precipitation and then filtered, the obtained precipitate is redissolved with tetrahydrofuran until it is just completely dissolved, and after dissolution, the solution is precipitated again with anhydrous ether or methyl tert-butyl ether, filtered, and the dissolution and precipitation filtering are repeated at least three times to obtain a copolymer precipitate A;

[0015] S4, drying the copolymer precipitate A in step S3;

[0016] S5, taking the copolymer precipitate in S4, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, adding chloroform to dissolve to obtain solution B;

[0017] S6, taking distearoylphosphatidylethanolamine, adding chloroform to dissolve, and adding triethylamine to obtain solution C;

[0018] S7, adding solution C to solution B, passing nitrogen, and sealing the mixture at 3°C ​​for 24 hours;

[0019] S8, after the reaction is completed, remove chloroform by rotary evaporation, dissolve with tetrahydrofuran, add the dissolved solution into anhydrous ether or methyl tert-butyl ether for precipitation and filtration, redissolve the obtained precipitate with tetrahydrofuran until it is just completely dissolved, and after dissolution, precipitate the solution again with anhydrous ether or methyl tert-butyl ether, filter, and repeat the dissolution and precipitation filtration at least three times to obtain copolymer precipitate D;

[0020] S9, drying the copolymer precipitate D in S8 to finally obtain a potassium ion recognition copolymer.

[0021] Furthermore, the molar ratio of 2-(dodecyl trithiocarbonate)-2-methylpropionic acid, N-isopropylacrylamide and azobisisobutyronitrile in step S1 is 1:(100-200):(0.05-0.5); the molar amount of benzo-15-crown-5-acrylamide accounts for 10%-40% of the sum of the molar amounts of benzo-15-crown-5-acrylamide, N-isopropylacrylamide and N,N-dimethylacrylamide, and the amount of 1,4-dioxane used should make the concentration of N-isopropylacrylamide in the mixed solution 10-30wt%.

[0022] The present invention also discloses a method for preparing a novel potassium ion responsive drug-loaded liposome, which comprises the following steps:

[0023] ST1, taking phospholipids, cholesterol and the potassium ion recognition copolymer, adding organic solution to fully dissolve;

[0024] ST2, rotary evaporating the solution in step ST1 to remove the organic solvent, and then adding an aqueous solution to prepare potassium ion recognition liposomes;

[0025] ST3, using ultrasound, membrane extrusion, shearing, and homogenization to control the particle size of liposomes;

[0026] ST4. Load the drug into the blank liposomes in step ST3 by active drug loading or passive drug loading according to the type of drug loaded, so as to obtain potassium ion responsive drug loaded liposomes.

[0027] Furthermore, the phospholipids include any one or more of soybean lecithin, egg choline, HSPC, DHPC, DPPC or their synthetic phospholipids.

[0028] Furthermore, the organic solvent includes chloroform, dichloromethane, tetrahydrofuran or methanol.

[0029] Furthermore, the aqueous phase solution includes sucrose aqueous solution, glucose aqueous solution, buffer solution or physiological saline.

[0030] Furthermore, the drugs include doxorubicin, dacarbazine, temozolomide, fotemustine, paclitaxel, cisplatin and carboplatin.

[0031] The self-assembly mechanism of the potassium ion responsive drug-loaded liposomes of the present invention is as follows:

[0032] The potassium ion recognition copolymer was synthesized by a two-step method of reversible addition-fragmentation chain transfer radical polymerization (RAFT) and condensation reaction, with distearoylphosphatidylethanolamine (DSPE) with good biocompatibility as the hydrophobic part and a copolymer of N-isopropylacrylamide (NIPAM), benzo-15-crown-5-acrylamide (B15C5Am) and N,N-dimethylacrylamide (DMAm) as the hydrophilic part. The 15-crown-5 in the copolymer can selectively complex K + , in complex K + After that, its LSCT migrates to low temperature, and the hydrophobicity of the copolymer is enhanced. The potassium ion recognition type drug-loaded liposome of the present invention is a liposome formed by modifying the surface of the liposome with a potassium ion recognition type copolymer, and the drug is encapsulated in the liposome. After the drug-loaded liposome enters the blood circulation, due to the extracellular K + The concentration (3.5-5.5 mmol / L) is relatively low, and liposomes are very sensitive to low concentration K + The responsiveness is small, and the LCST of the drug-loaded liposomes is higher than body temperature. The body temperature will not have much effect on their morphology, and the drug-loaded liposomes still maintain a good monodispersity state. When the drug-loaded liposomes reach the tumor microenvironment, due to the K +The concentration (40-50 mmol / L) is relatively high, and the copolymer specifically complexes potassium ions, thereby enhancing the surface hydrophobicity of the drug-loaded liposomes, and the liposomes can self-assemble through hydrophobic association.

[0033] The beneficial effects of the present invention are as follows: potassium ion recognition liposomes change from hydrophilic to hydrophobic after recognizing abnormal concentrations of potassium ions in the tumor microenvironment. The enhanced lipophilicity of the liposome surface is conducive to tumor cell uptake. The liposomes self-assemble due to hydrophobic association, which increases the retention time and accumulation rate at the tumor site and enhances the efficacy of the drug. At the same time, the entire preparation method is simple, has good biocompatibility, can be loaded with hydrophilic drugs, hydrophobic drugs and nucleic acid drugs, and can be used as a universal new type of targeted intelligent nano drug delivery system.

[0034] In general, the present invention prolongs the retention time in tumor tissue and enhances the uptake rate of tumor cells, thereby improving the efficacy of drugs, which is of great significance for the treatment of tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 (A)(B)(C)(D) are the infrared spectra of B15C5Am, PNB, PNB-DSPE and DSPE respectively;

[0036] Figure 2 (A) and (B) are the NMR spectra of PNB and PNB-DSPE, respectively;

[0037] Figure 3 The transmittance variation curves of PNB and PNB-DSPE in water and K+ solution (A) and LCST values ​​(B) are shown respectively;

[0038] Figure 4 The morphology (A), particle size distribution (B), UV spectrum (C) and encapsulation efficiency (D) of LIP-DOX and PNB-LIP-DOX;

[0039] Figure 5 This is the potassium ion recognition performance curve of LIP-DOX and PNB-LIP-DOX.

[0040] Among them, B15C5Am is benzo-15-crown-5-acrylamide; PNB is poly(N-isopropylacrylamide-co-benzo-15-crown-5-acrylamide-co-N,N-dimethylacrylamide); PNB-DSPE is poly(N-isopropylacrylamide-co-benzo-15-crown-5-acrylamide-co-N,N-dimethylacrylamide)-co-distearoylphosphatidylethanolamine; DSPE is co-distearoylphosphatidylethanolamine; LIP-DOX is a common liposome; PNB-LIP-DOX is a drug-loaded liposome. DETAILED DESCRIPTION

[0041] The present invention will be further described in detail below with reference to specific embodiments and accompanying drawings.

[0042] A novel potassium ion responsive drug-loaded liposome, which is composed of a potassium ion recognition copolymer modified drug-loaded liposome, wherein the drug content in the drug-loaded liposome is 3-10wt%; the particle size of the drug-loaded liposome is 70-200nm, and the potassium ion recognition copolymer is poly(N-isopropylacrylamide-co-benzo-15-crown-5-acrylamide-co-N,N-dimethylacrylamide)-co-distearoylphosphatidylethanolamine (PNB-DSPE), and its structural formula is as follows:

[0043]

[0044] Among them, y / (x+y+z)=0.1~0.4, z / (x+y+z)=0.2~0.5, x+y+z=10~300.

[0045] The preparation method of potassium ion responsive drug-loaded liposomes is as follows:

[0046] ST1, taking phospholipids, cholesterol and the potassium ion recognition copolymer, adding organic solution to fully dissolve;

[0047] ST2, rotary evaporating the solution in step ST1 to remove the organic solvent, and then adding an aqueous solution to prepare potassium ion recognition liposomes;

[0048] ST3, using any method such as ultrasound, membrane extrusion, shearing or homogenization to control the liposome particle size;

[0049] ST4. Load the drug into the blank liposomes in step ST3 by active drug loading or passive drug loading according to the type of drug loaded, so as to obtain potassium ion responsive drug loaded liposomes.

[0050] Wherein, the phospholipids include any one or more of soybean lecithin, egg choline, HSPC, DHPC, DPPC or their synthetic phospholipids. The organic solvent includes chloroform, dichloromethane, tetrahydrofuran or methanol. The aqueous phase solution includes sucrose aqueous solution, glucose aqueous solution, buffer solution or physiological saline. The drugs include doxorubicin, dacarbazine, temozolomide, fotemustine, paclitaxel, cisplatin and carboplatin.

[0051] Embodiment 1:

[0052] In this experimental example, a copolymer, poly(N-isopropylacrylamide-co-benzo-15-crown-5-acrylamide-co-N,N-dimethylacrylamide)-co-distearoylphosphatidylethanolamine (PNB-DSPE), was prepared by the following method:

[0053] Weigh N-isopropylacrylamide (NIPAM), benzo-15-crown-5-acrylamide (B15C5Am), azobisisobutyronitrile (AIBN), N,N-dimethylacrylamide (DMAm), and 2-(dodecyltrithiocarbonate)-2-methylpropionic acid, add 1,4-dioxane to dissolve, introduce nitrogen into the solution for 20 minutes to remove oxygen in the solution, seal and react at 70°C for 6 hours, dilute the reaction solution with tetrahydrofuran after the reaction, add the diluted reaction solution to a large amount of methyl tert-butyl ether for precipitation and then filter, redissolve the obtained precipitate with an appropriate amount of tetrahydrofuran, and then precipitate the solution with a large amount of methyl tert-butyl ether and filter, dissolve the precipitate three times according to the above steps, and vacuum dry the final copolymer precipitate to obtain poly(N-isopropylacrylamide-co-benzo-15-crown-5-acrylamide-co-N,N-dimethylacrylamide) (PNB) copolymer;

[0054] PNB copolymer, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide were weighed, and chloroform was added to dissolve. Distearoylphosphatidylethanolamine (DSPE) was weighed, and chloroform was added to dissolve. An appropriate amount of triethylamine was added, and the DSPE solution was dropped into the copolymer solution. After nitrogen was passed for 20 minutes, the mixture was sealed and reacted at 3°C ​​for 24 hours. After the reaction was completed, the chloroform was removed by rotary evaporation, and the mixture was dissolved with tetrahydrofuran. The mixture was precipitated with methyl tert-butyl ether and filtered. The precipitate was re-dissolved with an appropriate amount of tetrahydrofuran, and then the solution was precipitated with a large amount of methyl tert-butyl ether and filtered. The precipitate was dissolved three times according to the above steps, and the copolymer precipitate finally obtained was vacuum dried to obtain poly(N-isopropylacrylamide-co-benzo-15-crown-5 acrylamide-co-N,N-dimethylacrylamide)-co-distearoylphosphatidylethanolamine (PNB-DSPE) copolymer.

[0055] The molar ratio of the 2-(dodecyl trithiocarbonate)-2-methylpropionic acid, NIPAM and AIBN is 1:150:0.2, and the molar amount of the B15C5Am accounts for 20% of the sum of the molar amounts of B15C5Am, NIPAM and DMAm.

[0056] The infrared spectra of B15C5Am, PNB prepared in this example, PNB-DSPE prepared in this example and DSPE are shown in FIG. Figure 1 (A)(B)(C)(D) shown, 1367cm -1 and 1386cm -1 (-CH(CH3)2) is the characteristic absorption peak of NIPAM, 1513 cm -1 (arom.) and 1130cm -1(CO) is the characteristic absorption peak of B15C5Am, 1742cm -1 (OC=O) is the characteristic peak of DSPE, and the characteristic absorption peaks of NIPAM and B15C5Am appear in the infrared spectra of PNB and PNB-DSPE. In addition, the characteristic absorption peak of DSPE also appears in the infrared spectrum of PNB-DSPE, indicating that PNB and PNB-DSPE copolymers were successfully prepared in this example.

[0057] The NMR spectra of PNB and PNB-DSPE prepared in this example are as follows: Figure 2 As shown in (A) and (B), the following identical chemical shifts are shown: the chemical shift of the hydrogen atoms on the benzene ring in B15C5Am appears at around 7ppm, the chemical shift of the hydrogen atoms on the two methyl groups on the isopropyl group in NIPAM is at around 1ppm, and the chemical shift of the hydrogen atoms on the two methyl groups in DMAm is at around 2.8ppm. The above NMR data further illustrate that PNB and PNB-DSPE copolymers were successfully synthesized in this embodiment.

[0058] Embodiment 2:

[0059] In this experimental example, the potassium ion responsiveness of the PNB-DSPE copolymer prepared in Experimental Example 1 was determined. A temperature-controlled UV-visible spectrophotometer was used to characterize the potassium ion responsiveness of the PNB-DSPE copolymer in a normal tissue simulation fluid (5 mM K + +150mM Na + ) and tumor microenvironment simulation fluid (45mM K + +110mM Na + ) was measured to investigate its potassium ion responsiveness. The concentration of the copolymer was 0.1 wt % when measuring the potassium ion responsiveness.

[0060] like Figure 3 As shown, PNB-DSPE in high K + The LCST at concentrations is lower than that at low K + The concentration shifts significantly to lower temperatures, showing a better K + Responsiveness: When the temperature is 37°C, PNB-DSPE is hydrophilic in normal tissue simulation fluid and hydrophobic in tumor microenvironment simulation fluid and intracellular fluid simulation fluid, and can be used to construct drug-loaded liposomes that are responsive to potassium ions under physiological conditions. The LCST of drug-loaded liposomes in normal tissue simulation fluid is higher than body temperature, and body temperature will not have much effect on their morphology. The drug-loaded liposomes can maintain a good monodisperse state. When the drug-loaded liposomes reach the tumor microenvironment, due to the K +At high concentrations, the copolymers specifically complex potassium ions, thereby enhancing the surface hydrophobicity of the drug-loaded liposomes, and the liposomes can self-assemble through hydrophobic association.

[0061] Embodiment 3:

[0062] In this experimental example, the PNB-DSPE copolymer prepared in Experimental Example 1 was used to construct potassium ion recognition drug-loaded liposomes.

[0063] Soy lecithin, cholesterol, and PNB-DSPE were weighed separately and placed in a 50 ml round-bottom flask, 3 ml of chloroform was added to dissolve (the molar ratio of soybean lecithin: cholesterol: PNB-DSPE was 7.5:5:1), chloroform was removed at room temperature by reduced pressure rotary evaporation, and a transparent film was quickly formed at the bottom of the flask, 4 ml of 0.3 mol / L ammonium sulfate solution was added, and ultrasonic cleaning was first performed at 25°C for 2 min, and then ultrasonicated by a cell disruptor probe for 5 min, and dialyzed with 5% glucose solution overnight to obtain a blank liposome suspension; doxorubicin (drug-to-lipid ratio = 1:10) was weighed, dissolved with 5% glucose solution, added to the blank liposome, incubated at 37°C for 30 min, and the sample was dialyzed in 5% glucose solution, and the ultraviolet absorbance was measured regularly until the absorbance did not change, thereby preparing drug-loaded liposomes (PNB-LIP-DOX). The same method as above was used to prepare a control group of drug-loaded liposomes (LIP-DOX) that were not responsive to potassium ions without adding PNB-DSPE.

[0064] Transmission electron microscopy was used to characterize the morphology and particle size of PNB-LIP-DOX and LIP-DOX liposomes, DLS was used to characterize the particle size distribution of liposomes, and UV-visible spectrophotometer was used to investigate the encapsulation efficiency (EE) of liposomes. The encapsulation efficiency of liposomes was calculated according to the following formula:

[0065]

[0066] Where: W total ——Total mass of drug in liposomal suspension;

[0067] W free ——The quality of free drug.

[0068] The drug-loaded liposomes were placed in a refrigerator at 2-8°C, and their encapsulation efficiency was tested regularly to evaluate their stability. The PNB-LIP-DOX and LIP-DOX liposomes were tested by DLS in a tumor microenvironment simulation solution (45 mM K + +110mM Na + ) was used to characterize the potassium ion self-assembly response performance of liposomes.

[0069] like Figure 4As shown, both the common liposomes (LIP-DOX) loaded with doxorubicin and the liposomes (PNB-LIP-DOX) modified with PNB-DSPE have good morphology and monodispersity, with particle sizes of about 120nm and 100nm, respectively. The characteristic peaks of the UV spectrum indicate the successful synthesis of PNB-LIP-DOX liposomes. The encapsulation efficiency of PNB-LIP-DOX is about 85%, and it has good stability.

[0070] like Figure 5 As shown in Figure 2, as the temperature increases, PNB-LIP-DOX liposomes in the tumor microenvironment simulation fluid (45 mM K + +110mM Na + ) showed certain potassium ion recognition self-assembly performance. At 37°C, the ratio of the particle size of PNB-LIP-DOX liposomes to that at 25°C was approximately 2.2, showing good potassium ion recognition self-assembly performance.

[0071] The technical solutions provided by the embodiments of the present invention are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present invention. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present invention. At the same time, for those skilled in the art, according to the embodiments of the present invention, there will be changes in the specific implementation methods and application scopes. In summary, the content of this specification should not be understood as limiting the present invention.

Claims

1. A novel potassium ion responsive drug-loaded liposome, characterized in that: The liposome is composed of a potassium ion recognition copolymer modified drug-loaded liposome, and the drug is embedded in the inner core of the liposome, wherein the content of the drug in the drug-loaded liposome is 3-10wt%; the particle size of the drug-loaded liposome is 70-200nm, and the potassium ion recognition copolymer is poly(N-isopropylacrylamide-co-benzo-15-crown-5-acrylamide-co-N,N-dimethylacrylamide)-co-distearoylphosphatidylethanolamine, and its structural formula is as follows: Among them, y / (x+y+z)=0.1~0.4, z / (x+y+z)=0.2~0.5, x+y+z=10~300.

2. A novel potassium ion responsive drug-loaded liposome according to claim 1, characterized in that: The preparation method of the potassium ion recognition copolymer is as follows: S1. Take N-isopropylacrylamide, benzo-15-crown-5 acrylamide, azobisisobutyronitrile, N,N-dimethylacrylamide, and 2-(dodecyl trithiocarbonate)-2-methylpropionic acid, and add 1,4-dioxane to dissolve; S2, introducing nitrogen into the solution in step S1 to remove oxygen in the solution, and sealing and reacting at a temperature of 60°C to 80°C for 6 to 24 hours; S3. After the reaction is completed, the reaction solution is diluted with tetrahydrofuran, the diluted reaction solution is added to anhydrous ether or methyl tert-butyl ether for precipitation and then filtered, the obtained precipitate is redissolved with tetrahydrofuran until it is just completely dissolved, and after dissolution, the solution is precipitated again with anhydrous ether or methyl tert-butyl ether, filtered, and the dissolution and precipitation filtering are repeated at least three times to obtain a copolymer precipitate A; S4, drying the copolymer precipitate A in step S3; S5, taking the copolymer precipitate in S4, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, adding chloroform to dissolve to obtain solution B; S6, taking distearoylphosphatidylethanolamine, adding chloroform to dissolve, and adding triethylamine to obtain solution C; S7, adding solution C to solution B, passing nitrogen, and sealing the mixture at 3°C ​​for 24 hours; S8, after the reaction is completed, remove chloroform by rotary evaporation, dissolve with tetrahydrofuran, add the dissolved solution into anhydrous ether or methyl tert-butyl ether for precipitation and filtration, redissolve the obtained precipitate with tetrahydrofuran until it is just completely dissolved, and after dissolution, precipitate the solution again with anhydrous ether or methyl tert-butyl ether, filter, and repeat the dissolution and precipitation filtration at least three times to obtain copolymer precipitate D; S9, drying the copolymer precipitate D in S8 to finally obtain a potassium ion recognition copolymer.

3. A novel potassium ion responsive drug-loaded liposome according to claim 2, characterized in that: The molar ratio of 2-(dodecyl trithiocarbonate)-2-methylpropionic acid, N-isopropylacrylamide and azobisisobutyronitrile in step S1 is 1:(100-200):(0.05-0.5); the molar amount of benzo-15-crown-5-acrylamide accounts for 10%-40% of the sum of the molar amounts of benzo-15-crown-5-acrylamide, N-isopropylacrylamide and N,N-dimethylacrylamide, and the amount of 1,4-dioxane used should make the concentration of N-isopropylacrylamide in the mixed solution 10-30wt%.

4. A method for preparing a novel potassium ion responsive drug-loaded liposome according to any one of claims 1 to 3, characterized in that: The following steps are included: ST1, taking phospholipids, cholesterol and the potassium ion recognition copolymer, adding organic solution to fully dissolve; ST2, rotary evaporating the solution in step ST1 to remove the organic solvent, and then adding an aqueous solution to prepare potassium ion recognition liposomes; ST3, using ultrasound, membrane extrusion, shearing or homogenization to regulate the liposome particle size; ST4. Load the drug into the blank liposomes in step ST3 by active drug loading or passive drug loading according to the type of drug loaded, so as to obtain potassium ion responsive drug loaded liposomes.

5. The method for preparing a novel potassium ion responsive drug-loaded liposome according to claim 4, characterized in that: The phospholipids include any one or more of soybean lecithin, egg choline, HSPC, DHPC, DPPC or their synthetic phospholipids.

6. The method for preparing a novel potassium ion responsive drug-loaded liposome according to claim 4, characterized in that: The organic solvent includes chloroform, dichloromethane, tetrahydrofuran or methanol.

7. The method for preparing a novel potassium ion responsive drug-loaded liposome according to claim 4, characterized in that: The aqueous phase solution includes sucrose aqueous solution, glucose aqueous solution, buffer solution or physiological saline.

8. The method for preparing a novel potassium ion responsive drug-loaded liposome according to claim 4, characterized in that: The drugs include doxorubicin, dacarbazine, temozolomide, fotemustine, paclitaxel, cisplatin, and carboplatin.